Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities: 2009-2024
Historic Cash from Investing Activities for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to $52.6 million.
- Biocryst Pharmaceuticals' Cash from Investing Activities rose 94.37% to -$3.0 million in Q4 2015 from the same period last year, while for Dec 2015 it was -$18.0 million, marking a year-over-year increase of 54.97%. This contributed to the annual value of $52.6 million for FY2024, which is 140.00% up from last year.
- Biocryst Pharmaceuticals' Cash from Investing Activities amounted to $52.6 million in FY2024, which was up 140.00% from -$131.5 million recorded in FY2023.
- Biocryst Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $52.6 million during FY2024, with a 5-year trough of -$131.5 million in FY2023.
- In the last 3 years, Biocryst Pharmaceuticals' Cash from Investing Activities had a median value of -$128.2 million in 2022 and averaged -$69.0 million.
- In the last 5 years, Biocryst Pharmaceuticals' Cash from Investing Activities soared by 330.51% in 2021 and then plummeted by 911.43% in 2022.
- Over the past 5 years, Biocryst Pharmaceuticals' Cash from Investing Activities (MRY) stood at -$6.9 million in 2020, then skyrocketed by 330.51% to $15.8 million in 2021, then plummeted by 911.43% to -$128.2 million in 2022, then dropped by 2.54% to -$131.5 million in 2023, then soared by 140.00% to $52.6 million in 2024.
- Its last three reported values are $52.6 million in FY2024, -$131.5 million for FY2023, and -$128.2 million during FY2022.